Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Novartis AG
NVS
$151.22
Name : Novartis AG
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $285,597,663,232.00
EPSttm : 5.24
finviz dynamic chart for NVS
Novartis AG
$151.22
2.57%
$3.99
NVS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.25

Margin Of Safety %

9

Put/Call OI Ratio

2.44

EPS Next Q Diff

-0.19

EPS Last/This Y

1.86

EPS This/Next Y

0.86

Price

151.22

Target Price

159.5

Analyst Recom

2

Performance Q

-4.79

Upside

-23.8%

Beta

0.42

Ticker: NVS




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-21NVS153.962.301.98100721
2026-10-22NVS156.292.2723.39100381
2026-10-23NVS151.122.555.98109454
2026-10-26NVS153.812.303.51103363
2026-10-27NVS156.852.302.06105601
2026-10-28NVS156.062.234.52103496
2026-10-29NVS161.042.246.02104690
2026-10-30NVS160.822.387.99111432
2026-11-02NVS161.482.691.90124718
2026-11-03NVS159.262.4311.96116762
2026-11-04NVS164.982.486.94118796
2026-11-05NVS161.932.527.15122187
2026-11-06NVS162.552.606.47126307
2026-11-09NVS163.692.667.09130502
2026-11-10NVS163.32.692.53131985
2026-11-11NVS160.422.641.24135586
2026-11-12NVS160.272.610.47136363
2026-11-13NVS160.532.602.60137101
2026-11-16NVS160.212.581.13136808
2026-11-17NVS159.092.571.27139091
2026-11-18NVS155.252.5110.71140316
2026-11-19NVS151.472.4428.09140754
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-21NVS153.61-0.45350.58.83
2026-10-22NVS156.29-0.45212.88.83
2026-10-23NVS151.12-0.44286.68.83
2026-10-26NVS153.77-0.45245.08.83
2026-10-27NVS156.80-0.45288.98.83
2026-10-28NVS156.07-0.47513.28.83
2026-10-29NVS161.0413.98223.19.17
2026-10-30NVS160.6913.98009.09.17
2026-11-02NVS161.469.98140.89.15
2026-11-03NVS159.239.97870.09.16
2026-11-04NVS165.029.98766.09.16
2026-11-05NVS161.919.97689.59.16
2026-11-06NVS162.639.98380.59.16
2026-11-09NVS163.699.98434.89.16
2026-11-10NVS163.259.98241.69.16
2026-11-11NVS160.369.97942.79.16
2026-11-12NVS160.269.98288.19.16
2026-11-13NVS160.539.98330.09.17
2026-11-16NVS160.169.98235.99.17
2026-11-17NVS159.129.98161.89.07
2026-11-18NVS155.269.97810.59.07
2026-11-19NVS151.229.97788.79.07
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-21NVS0.00-0.250.31
2026-10-22NVS0.00-0.250.31
2026-10-23NVS0.00-0.250.31
2026-10-26NVS0.00-0.320.31
2026-10-27NVS0.00-0.320.31
2026-10-28NVS0.00-0.320.31
2026-10-29NVS0.00-0.320.31
2026-10-30NVS0.00-0.320.31
2026-11-02NVS0.000.060.31
2026-11-03NVS0.000.060.31
2026-11-05NVS0.000.060.31
2026-11-06NVS0.000.060.31
2026-11-09NVS0.007.780.31
2026-11-10NVS0.007.780.31
2026-11-11NVS0.007.780.25
2026-11-12NVS0.007.780.25
2026-11-13NVS0.007.780.25
2026-11-16NVS0.007.710.25
2026-11-17NVS0.007.710.25
2026-11-18NVS0.007.710.25
2026-11-19NVS0.007.710.25
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

2.46

Avg. EPS Est. Current Quarter

2.23

Avg. EPS Est. Next Quarter

2.27

Insider Transactions

Institutional Transactions

7.71

Beta

0.42

Average Sales Estimate Current Quarter

14830

Average Sales Estimate Next Quarter

14309

Fair Value

165.44

Quality Score

91

Growth Score

79

Sentiment Score

38

Actual DrawDown %

11.3

Max Drawdown 5-Year %

-20.4

Target Price

159.5

P/E

28.89

Forward P/E

15.3

PEG

2.37

P/S

5

P/B

7.67

P/Free Cash Flow

17.7

EPS

5.24

Average EPS Est. Cur. Y​

9.07

EPS Next Y. (Est.)

9.93

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

18.14

Relative Volume

1.66

Return on Equity vs Sector %

0.4

Return on Equity vs Industry %

-7.8

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.24

EBIT Estimation

7788.7
◆ NVS Healthcare
$151.25
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
8/20
Pullback
13/25
Volume
3/15
Valuation
12/20
TP/AR
1/10
Options
1/10
RSI
39.7
Range 1M
11%
🚀
Momentum Growth
Ride accelerating trends
N/A
31 /100
WEAK
Momentum
5/25
Growth
9/30
Estimates
5/20
Inst/Vol
9/15
Options
3/10
EPS Yr
-0.8%
EPS NY
10.9%
52W%
58.8%
💎
Long-Term Value
Quality companies, undervalued
44 /100
WEAK
🟡 HOLD +26.1% upside
Quality
23/30
Valuation
10/30
Growth
6/25
Stability
2/10
LT Trend
3/5
Upside
+26.1%
Quality
91
MoS
9%
NVS — P/E HistoricalDrug Manufacturers - General
Novartis AG
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75267
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
NVS

Latest News

—
Caricamento notizie per NVS…
stock quote shares NVS – Novartis AG Stock Price stock today
news today NVS – Novartis AG stock forecast ,stock prediction 2023 2024 2025
marketwatch NVS – Novartis AG yahoo finance google finance
stock history NVS – Novartis AG invest stock market
stock prices NVS premarket after hours
ticker NVS fair value insiders trading